-
Leerink Partners Upgrades Twist Bioscience (TWST) to Outperform
-
Twist Bioscience (TWST) PT Raised to $65 at Wolfe Research
-
Twist Bioscience (TWST) PT Raised to $68 at TD Cowen
-
Twist Bioscience Corporation (TWST) Misses Q2 EPS by 23c
-
Twist Bioscience launches complex gene synthesis service up to 7,000 base pairs
-
Barclays: Life science insiders sold $187M in stock during first quarter
-
Guggenheim Reiterates Buy Rating on Twist Bioscience (TWST)
-
TD Cowen Reiterates Top Pick on Halozyme Therapeutics (HALO)
-
Twist Bioscience licenses bispecific antibody platform from Invenra
-
Twist Bioscience (TWST) PT Raised to $45 at Leerink Partners
-
Twist Bioscience Corporation (TWST) Misses Q1 EPS by 7c
-
Twist Bioscience Corporation (TWST) Misses Q4 EPS by 4c
-
Stephens Starts Twist Bioscience (TWST) at Overweight
-
Twist Bioscience launches Trinity Freestyle workflow with Element
-
Twist Bioscience co-authors study on AI protein design biosecurity risks
-
Twist Bioscience partners with Synthetic Design Lab for cancer therapeutics
-
Twist Bioscience (TWST) PT Lowered to $25 at JPMorgan
-
Twist Bioscience (TWST) PT Lowered to $36 at TD Cowen
-
Twist Bioscience (TWST) PT Lowered to $46 at Evercore ISI
-
Twist Bioscience launches humanized transgenic mouse model for antibodies
-
Twist Bioscience Corporation (TWST) and Ginkgo Bioworks (DNA) Revise Collaboration
-
Leerink Partners Reiterates Market Perform Rating on Twist Bioscience (TWST)
-
Barclays on Twist Bioscience (TWST): 'recommend buy the dips'
-
Twist Bioscience (TWST) PT Lowered to $50 at Evercore ISI
-
TD Cowen on Twist Bioscience (TWST): 'Occam's Razor: Hitting Numbers, Closing Deals, Gaining Share + Upside Ahead'
-
Twist Bioscience Corporation (TWST) Misses Q2 EPS by 5c
-
Twist Bioscience Corporation (TWST) Spins Out DNA Data Storage as Independent Company
-
Twist Bioscience (TWST) PT Raised to $62 at Scotiabank
-
Twist Bioscience (TWST) PT Raised to $58 at Barclays
-
Twist Bioscience Corporation (TWST) Tops Q1 EPS by 10c
-
Baird Reiterates Outperform Rating on Twist Bioscience (TWST)
-
TD Cowen Reiterates Buy Rating on Twist Bioscience (TWST)
-
Twist Bioscience (TWST) PT Raised to $54 at Scotiabank
-
Twist Bioscience (TWST) PT Raised to $48 at Baird
-
TD Cowen Reiterates Buy Rating on Twist Bioscience (TWST)
-
Twist Bioscience Corporation (TWST) Tops Q4 EPS by 12c; offers guidance
-
Absci Corporation (ABSI) and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI
-
Twist Bioscience Corporation (TWST) Enters into Royalty Purchase Agreement with XOMA Royalty (XOMA) for $15 Million in Cash
-
Baird Reiterates Outperform Rating on Twist Bioscience (TWST)
-
Twist Bioscience Corporation (TWST) Appoints Mike Fero as Chief Information Officer
-
Baird Reiterates Outperform Rating on Twist Bioscience (TWST)
-
Baird Reiterates Outperform Rating on Twist Bioscience (TWST)
-
Twist Bioscience (TWST) Expands Gene Offering With Long Gene Fragments up to 5.0kb
-
Twist Bioscience Corporation (TWST) and bitBiome Announce Strategic Collaboration
-
Twist Bioscience Corporation (TWST) Misses Q3 EPS by 71c ; Offers Guidance
-
TD Cowen Reiterates Buy Rating on Twist Bioscience (TWST)
-
Twist Bioscience (TWST) PT Raised to $65 at TD Cowen

